Companies / South Korea
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Spurious Suits Safeguard Sales
May 2007 | Legal NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Multinational drugmakers are filing seemingly groundless legal actions against South Korean generic medicine producers in an effort to keep prices of patented medicines at current levels. Under the recently signed free trade agreement with the US, foreign drugmakers can challenge potential generic competitors in the courts, thereby preventing approval and pricing of cheaper equivalents. It is BMI's view that the majority of these cases will be dismissed, but until that time, big pharma will continue to charge high prices for its products in South